Presentation (CTI)

OBJECTIVES: Assess the economic benefits of a Tri-Layer Hybrid Surgical Mesh (HSM) vs. three alternative mesh devices including a permanent polypropylene mesh with absorbable coating ("Device A”), a reinforced hybrid biologic mesh (“Device B”), and a fully resorbable synthetic mesh (“Device C”), placed in the intraperitoneal plane for ventral-incisional hernia repair. Differences in resource use and the budget impact to an average large U.S. hospital were assessed.
METHODS: Cost-consequence and budget impact analyses were derived from patient outcomes identified for each device through a targeted literature review. The primary outcome measured was 90-day readmissions. Costs and reimbursement were sourced from publicly available fee-schedules and analysis of a large real-world database. The proportion of inpatient and outpatient cases and respective costs and reimbursement were calculated to account for differences in settings of care.
RESULTS: The 90-day readmission rate for HSM was 1.4% compared to 11.9%, 24% and 12.9% for devices A, B and C, respectively. The average 90-day cost per patient treated was lowest for HSM at $7,143 for HSM followed by device A at $9,705, device B at $13,328 and device C at $12,462. Modelling 100% adoption of HSM for a hospital performing 600 procedures annually led to an expected cost savings of $4,689 per patient treated over 90 days. Furthermore, this resulted in a projected budget impact of $2.81 Million in savings to the hospital. Sensitivity analyses showed results to be robust to reasonable changes in base input values.
CONCLUSIONS: This model shows that using the Tri-Layer Hybrid Surgical Mesh for ventral incisional hernia repair led to less resource use and substantial expected cost savings for an average US hospital compared to competitors, driven by lower readmission rates.